Para-Methoxyphenylpiperazine

Pharmacology

pMeOPP is anecdotally said to induce significantly less anxiety than similar piperazines, and is usually taken at doses between 120–200 mg. However it is often mixed with stimulant piperazine derivatives such as benzylpiperazine (BZP) for a combined effect.

pMeOPP has been found in vitro to inhibit the reuptake and induce the release of the monoamine neurotransmitters. This is a mechanism of action shared with drugs of abuse such as amphetamines, and pMeOPP produces somewhat similar effects although it is much less potent and is thought to have relatively insignificant abuse potential. Piperazine derivatives such as trifluoromethylphenylpiperazine (TFMPP) have also been shown to exert a major part of their mechanism of action as nonselective serotonin receptor agonists, and pMeOPP has also been demonstrated to act in this way.

Legal status

Finland

Scheduled in the "government decree on psychoactive substances banned from the consumer market".

New Zealand

Based on the recommendation of the EACD, the New Zealand government has passed legislation which placed BZP, along with a number of other piperazine derivatives into Class C of the New Zealand Misuse of Drugs Act 1975. A ban was intended to come into effect in New Zealand on December 18, 2007, but the law change did not go through until the following year, and the sale of BZP and the other listed piperazines became illegal in New Zealand as of 1 April 2008. An amnesty for possession and usage of these drugs remained until October 2008, at which point they became completely illegal.

United States

pMeOPP is not scheduled at the federal level in the United States.

Florida

"Methoxyphenylpiperazine" is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in Florida.

References

References

1. (2011). "Current awareness of piperazines: pharmacology and toxicology". Drug Test Anal.
2. (March 2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". European Journal of Pharmacology.
3. (April 2004). "Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis". Therapeutic Drug Monitoring.
4. "Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista". Finlex Data Bank.
5. [http://www.parliament.nz/en-NZ/PB/Legislation/Bills/d/3/d/00DBHOH_BILL8220_1-Misuse-of-Drugs-Classification-of-BZP-Amendment.htm Misuse of Drugs (Classification of BZP) Amendment Bill 2008]
6. "21 CFR — SCHEDULES OF CONTROLLED SUBSTANCES §1308.11 Schedule I.".
7. [http://leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL]